Gilead buying another NASH program for up to $470m
This article was originally published in Scrip
Executive Summary
Gilead Sciences has two market-leading drugs to treat hepatitis C and now the company is expanding its liver disease empire with the acquisition of small molecules for the treatment of non-alcoholic steatohepatitis (NASH) from Phenex Pharmaceuticals.
You may also be interested in...
Gilead Pays Phenex $100m Milestone As NASH Candidate Progresses
With hepatitis C wrapped up, NASH is becoming the focus of liver disease R&D. Gilead, which has a number of NASH programs, has paid Phenex $100m for clinical progress with an in-licensed candidate for NASH and other liver diseases.
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.